BioSpace News Archive

Olympus Corporation announced that it has exercised its call option in respect of the remainder of the shares in Medi-Tate Ltd.

Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, published its audited Financial Results for 2020 and the company’s 2020 Annual Report.

Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, announces its non-audited financial results for the year ended December 31, 2020, and provides updates on key operational developments and financing transactions.

Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with metastatic cancer.

China National Medical Products Administration announced on February 25 to grant conditional marketing authorization of Recombinant COVID-19 Vaccine .

40 per cent of Swedes with a rare condition, or their family members, state that a relationship has ended due to a rare condition, according to a study by Swedish biopharmaceutical company Sobi.

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 26 February 2021 consists of 441,378,190 ordinary shares of 1 pence each, none of which are held in treasury.

Amphastar Pharmaceuticals, Inc. announced that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Raymond James 2021 Institutional Healthcare Conference on Tuesday, March 2, 2021 at 1:20 pm Eastern time.

UPLIFT, a single-arm registration strategy evaluating upifitamab rilsodotin (UpRi) in platinum-resistant ovarian cancer, on track to begin in Q1 2021

Company granted 180 days of exclusivity under FDA Competitive Generic Therapy (CGT) approval pathway